Glucagon-Like Peptide-1 Receptor Agonist Market - Global Industry Research Analysis

Glucagon-like Peptide-1 Receptor Agonist Market Insights

According to Market Research Store, the global glucagon-like peptide-1 receptor agonist market size was valued at around USD 15.62 billion in 2023 and is estimated to reach USD 28.37 billion by 2032, to register a CAGR of approximately 6.10% in terms of revenue during the forecast period 2024-2032.

The glucagon-like peptide-1 receptor agonist report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.

Global Glucagon-Like Peptide-1 Receptor Agonist Market: Overview

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that mimic the action of the naturally occurring hormone GLP-1 in the body. GLP-1 is involved in the regulation of blood sugar levels by enhancing insulin secretion, inhibiting glucagon release (a hormone that raises blood sugar), slowing gastric emptying, and promoting satiety. These actions make Glucagon-like peptide-1 receptor agonist particularly effective for managing type 2 diabetes and, more recently, obesity. Glucagon-like peptide-1 receptor agonist work by binding to and activating the GLP-1 receptor, leading to improved glycemic control and reduced body weight. Some common Glucagon-like peptide-1 receptor agonist include drugs like liraglutide, semaglutide, and dulaglutide.

Key Highlights

• The Glucagon-like peptide-1 receptor agonist market is anticipated to grow at a CAGR of 23.70% during the forecast period.
• The global Glucagon-like peptide-1 receptor agonist market was estimated to be worth approximately USD 38.91 billion in 2023 and is projected to reach a value of USD 326.30 billion by 2032.
• The growth of the Glucagon-like peptide-1 receptor agonist market is being driven by the increasing prevalence of Type 2 diabetes and obesity worldwide.
• Based on the type, the Long-acting GLP-1 Agonists segment is growing at a high rate and is projected to dominate the market.
• In terms of route of administration, the parenteral segment is expected to dominate the market.
• Based on the distribution channel, the hospital pharmacies segment is expected to dominate the market.
• By region, North America is expected to dominate the global market during the forecast period.

Glucagon-Like Peptide-1 Receptor Agonist Market: Dynamics

Key Growth Drivers:

• Rising prevalence of type 2 diabetes and obesity: The global burden of type 2 diabetes and obesity is increasing at an alarming rate, driving the demand for effective treatment options.
• Increasing R&D activities: Pharmaceutical companies are investing heavily in research and development to develop new and improved Glucagon-like peptide-1 receptor agonist.
• Formulation advancements: Newer formulations of Glucagon-like peptide-1 receptor agonist, such as oral and once-weekly injections, are making these medications more convenient and accessible for patients.
• Increasing awareness about diagnosis and treatment options: Greater awareness among healthcare providers and patients about the benefits of Glucagon-like peptide-1 receptor agonist is also driving market growth.

Restraints:

• High cost of Glucagon-like peptide-1 receptor agonist: These medications can be expensive, making them inaccessible for some patients.
• Adverse effects: Some Glucagon-like peptide-1 receptor agonist can cause side effects such as nausea, vomiting, and diarrhea.
• Product recalls: There have been instances of product recalls due to safety concerns, which can negatively impact market growth.

Opportunities:

• Expanding indications: Glucagon-like peptide-1 receptor agonist are being investigated for the treatment of other conditions such as obesity, non-alcoholic fatty liver disease, and Alzheimer's disease.
• Development of new formulations: Ongoing research and development efforts are focused on developing more effective and convenient formulations of Glucagon-like peptide-1 receptor agonist.
• Emerging markets: The growing middle class in emerging economies is expected to drive demand for Glucagon-like peptide-1 receptor agonist.

Challenges:

• Competition: The glucagon-like peptide-1 receptor agonist market is highly competitive, with many pharmaceutical companies vying for market share.
• Stringent regulatory requirements: The development and approval of new Glucagon-like peptide-1 receptor agonist is subject to stringent regulatory requirements, which can increase the time and cost of bringing new products to market.
• Potential for generic competition: The entry of generic Glucagon-like peptide-1 receptor agonist could put downward pressure on prices.

Glucagon-like Peptide-1 Receptor Agonist Market: Report Scope

Glucagon-like peptide-1 receptor agonist Market: Segmentation Insights

The global Glucagon-like peptide-1 receptor agonist market is divided by type, route of administration, distribution channel, and region.

Segmentation Insights by Type

On the basis of type, the global Glucagon-like peptide-1 receptor agonist market is bifurcated into Short-acting GLP-1 Agonists and Long-acting GLP-1 Agonists.

The Long-acting GLP-1 Agonists segment dominates in terms of market share and growth potential, driven by their convenience, efficacy, and expanding indications. Long-acting GLP-1 agonists are administered less frequently, typically once weekly, offering sustained glucose control and additional benefits like weight loss and cardiovascular protection.

However, Short-acting GLP-1 Agonists retain importance for specific patient needs requiring rapid and meal-specific glucose control. Short-acting GLP-1 agonists are administered more frequently, typically daily or before meals, and primarily target postprandial glucose control by slowing gastric emptying and promoting insulin secretion.

Segmentation Insights by Route of Administration

In terms of route of administration, the global Glucagon-like peptide-1 receptor agonist market is categorized into parenteral and oral.

The parenteral route is currently the most dominant method of administration in the GLP-1 receptor agonist market. Parenteral drugs are typically administered through injection, and many of the leading Glucagon-like peptide-1 receptor agonist, such as Ozempic, Trulicity, and Wegovy, are delivered this way. The parenteral route offers several advantages, particularly in terms of drug absorption and bioavailability. Glucagon-like peptide-1 receptor agonist like Ozempic and Wegovy are injected subcutaneously, typically once a week, which is convenient for patients who prefer less frequent dosing. These medications have proven highly effective in managing both type 2 diabetes and obesity, with strong clinical outcomes that have helped establish them as the go-to treatments for these conditions. The once-weekly injection option has become particularly popular among patients, as it offers a balance of convenience and efficacy.

The oral route, although less dominant than parenteral administration, is gaining traction due to its convenience and patient preference. Rybelsus, the first oral GLP-1 receptor agonist, represents a significant advancement in this area. Unlike the injectable versions, Rybelsus is taken daily in tablet form, which appeals to patients who are hesitant to use injections. Although the oral form is still a relatively small player in the market compared to injectables, its ease of use has given it a unique niche, particularly for patients with type 2 diabetes who may be reluctant to start injectable therapies. The oral route is expected to grow in prominence as more oral formulations of Glucagon-like peptide-1 receptor agonist are developed and brought to market, although injectable therapies are likely to remain the dominant choice due to their long-acting formulations and proven efficacy.

Segmentation Insights by Distribution Channel

In terms of distribution channel, the global Glucagon-like peptide-1 receptor agonist market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies are one of the most important distribution channels, particularly for patients who are under medical supervision or require more specialized care. Glucagon-like peptide-1 receptor agonist are often prescribed in hospitals, especially for patients who have advanced or complex cases of type 2 diabetes or obesity. Hospital pharmacies play a key role in ensuring that patients receive the necessary medications during inpatient visits or outpatient appointments. These pharmacies typically offer more personalized care, with pharmacists working closely with healthcare providers to adjust treatment regimens based on individual patient needs. As a result, hospital pharmacies continue to be a dominant distribution channel for Glucagon-like peptide-1 receptor agonist, especially for newer or more specialized medications that may require more careful monitoring.

Retail pharmacies are the most commonly accessed channel for many patients seeking Glucagon-like peptide-1 receptor agonist. These pharmacies, which include chain pharmacies, independent drugstores, and clinics, provide easy access to medications for patients who are managing their diabetes or obesity on an outpatient basis. Retail pharmacies typically offer a broader selection of medications and are an essential point of access for Glucagon-like peptide-1 receptor agonist, especially for those who are on long-term treatment regimens. Drugs like Ozempic, Trulicity, and Wegovy are frequently dispensed at retail pharmacies, as these medications are commonly prescribed for type 2 diabetes and obesity. Retail pharmacies benefit from a well-established infrastructure, making it easier for patients to obtain their prescriptions and receive consultations on drug usage and side effects.

Online pharmacies, while still a smaller segment of the market compared to hospital and retail pharmacies, are seeing rapid growth as patients increasingly turn to digital platforms for convenience. Online pharmacies offer a convenient and discreet option for purchasing Glucagon-like peptide-1 receptor agonist, with patients able to place orders and have medications delivered directly to their homes. This distribution channel is particularly appealing to patients who value convenience, privacy, or those who may have difficulty visiting physical pharmacies. The growth of e-commerce and telemedicine has further propelled the expansion of online pharmacies, allowing patients with diabetes and obesity to more easily manage their medications. As the market for online pharmacies continues to expand, this distribution channel is expected to capture a larger share, especially among patients who are comfortable with digital health solutions.

Glucagon-Like Peptide-1 Receptor Agonist Market: Regional Insights

• North America is expected to dominates the global market

North America leads the global glucagon-like peptide-1 receptor agonist market, driven by a robust healthcare infrastructure and high patient adoption rates. The United States, in particular, has a significant market share, with a large proportion of adults utilizing GLP-1 drugs such as semaglutide (Ozempic and Wegovy). This widespread use is supported by extensive healthcare coverage and a high prevalence of type 2 diabetes and obesity among the population.

Europe also holds a substantial share of the market, with countries like the United Kingdom, France, and Germany contributing significantly to the demand for Glucagon-like peptide-1 receptor agonist. The aging population and increasing rates of metabolic disorders in these nations have led to a higher adoption of these treatments. Additionally, the presence of leading pharmaceutical companies and favorable regulatory environments have facilitated the availability and acceptance of these medications.

The Asia Pacific region is experiencing rapid growth in the glucagon-like peptide-1 receptor agonist market, with countries such as China, India, and Japan showing increasing adoption rates. This growth is attributed to rising healthcare expenditures, a growing burden of diabetes and obesity, and expanding access to advanced medical treatments. International pharmaceutical companies are actively entering these markets, recognizing the significant potential due to large patient populations and evolving healthcare systems.

Latin America is witnessing a growing demand for Glucagon-like peptide-1 receptor agonist, driven by increasing urbanization and lifestyle changes leading to higher rates of diabetes and obesity. Countries like Brazil are becoming more proactive in seeking preventive care and treatment for these conditions, thereby boosting the market for these medications. The region's expanding healthcare infrastructure and rising awareness about metabolic disorders are contributing to this upward trend.

In the Middle East and Africa, the glucagon-like peptide-1 receptor agonist market is expanding, influenced by factors such as high prevalence of diabetes and obesity, along with increasing healthcare initiatives. Countries like Saudi Arabia are focusing on public health campaigns to raise awareness about these conditions, leading to a higher demand for effective treatments. The region's growing healthcare investments and improving access to medical care are also facilitating the adoption of these therapies.

Recent Developments:

• In August 2024, Eli Lilly announced that Tirzepatide (Zepbound and Mounjaro) reduced the risk of developing type 2 diabetes by 94% in adults with prediabetes and obesity or overweight, based on the SURMOUNT-1 study. The 176-week trial showed an average 22.9% weight loss with the 15 mg dose, while also demonstrating consistent safety and tolerability.
• In July 2024, Amylyx Pharmaceuticals acquired Avexitide, a GLP-1 receptor agonist from Eiger Biopharmaceuticals, with FDA breakthrough therapy designation for treating Postbariatric Hypoglycemia (PBH) and congenital hyperinsulinism. Avexitide demonstrated significant efficacy in reducing severe hypoglycemic events in Phase 2 trials and is set to enter Phase 3 trials for PBH in early 2025.
• In February 2024, Eli Lilly announced plans to launch Mounjaro, its successful medication for diabetes and obesity, in India as early as next year, pending regulatory approval. The launch is expected to positively impact market growth in India.

Glucagon-Like Peptide-1 Receptor Agonist Market: Competitive Landscape

The report provides an in-depth analysis of companies operating in the glucagon-like peptide-1 receptor agonist market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.

Some of the major players in the global glucagon-like peptide-1 receptor agonist market include:

• GSK
• Novo Nordisk
• Haosoh
• Sanofi
• AstraZeneca
• Eli Lilly and Company

The global glucagon-like peptide-1 receptor agonist market is segmented as follows:

By Type

• Short-acting GLP-1 Agonists
• Long-acting GLP-1 Agonists

By Route of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East Africa

Frequently Asked Questions